The DOI matches its Crossref record; 271 of the 271 references it cites were found in a registry or an index.
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Open accessAbstract
The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) initiated the hepatitis C virus (HCV) guidance project (hereafter HCV guidance) in 2013. The AASLD-IDSA HCV guidance website (www.HCVGuidelines.org) disseminates up-to-date, peer-reviewed, unbiased, evidence-based recommendations to aid clinicians making decisions regarding the testing, management, and treatment of HCV infection. Using a web-based system enables timely and nimble distribution of the HCV guidance, which is periodically updated in near real time as necessitated by emerging research data, recommendations from public health agencies, the availability of therapeutic agents, or other significant developments affecting the rapidly evolving hepatitis C arena. The value and utility of the online HCV guidance to the community of hepatitis C care providers throughout the world is evidence by the nearly 10 million pageviews by 1.5 million users originating from 228 countries and territories since the January 2014 launch of the website. A major update of the HCV guidance was released electronically in November 2019. This HCV guidance update summarizes and highlights key new or amended recommendations since the previous October 2018 print publication.1 The advent of safe, well-tolerated, and highly efficacious (>95% cure rate)2 direct-acting antiviral (DAA) therapy for HCV infection has ushered in an era in which elimination of hepatitis C is conceivable. In 2016, the World Health Organization (WHO) proposed a global health sector strategy to eliminate hepatitis C as a public health threat by 2030 and developed an action plan to facilitate this goal.3 In response to the WHO action plan, the National Academies of Science, Engineering, and Medicine (NASEM) developed a US strategy for the elimination of hepatitis C.4 Key elements of the elimination plan include improved detection of undiagnosed cases, increased linkage and access to care for newly diagnosed persons, and expanded treatment access. Many of the recommendations included in the latest update to the HCV guidance and highlighted herein align with and support the goals of the NASEM and WHO strategies to move from control to eventual elimination of hepatitis C. Topics addressed include universal and risk-based hepatitis C screening, simplified treatment algorithms for treatment-naive adults without cirrhosis or with compensated cirrhosis, hepatitis C management in the pediatric population, acute hepatitis C testing and management, and transplantation of organs from HCV-viremic donors into HCV-negative recipients. For detailed evidence reviews related to these topics and information addressing other aspects of HCV testing and management, see the online HCV guidance (www.HCVGuidelines.org). The HCV guidance was developed and is updated by a volunteer panel (representing the AASLD and the IDSA) of hepatology and infectious diseases clinicians with hepatitis C expertise using an evidence-based review of available data, including information presented at scientific conferences and published in peer-reviewed journals. Based on scientific evidence and expert opinion, recommendations are rated by the level of evidence (I, II, or III) and the strength of the recommendation (A, B, or C) using a system adapted from the American College of Cardiology and the American Heart Association.5, 6 See the original AASLD–IDSA hepatitis C guidance publication7 or the HCV guidance website for additional details about the processes and methods employed. All recommendations are reviewed and approved by the governing boards of the AASLD and the IDSA. The HCV guidance panel classifies therapeutic regimens as recommended, alternative, or not recommended based on patient factors (i.e., treatment-naive versus experienced, cirrhosis status, and comorbidities) and viral characteristics (i.e., genotype, subtype, resistance-associated substitutions). Recommended regimens are considered equivalent; alternative regimens are effective but, compared to recommended regimens, have potential disadvantages, limitations for use in certain patient populations, or less supporting data. The identification of risk factors associated with contracting HCV infection served as the basis for the risk-based hepatitis C screening recommendations issued by the US Centers for Disease Control and Prevention (CDC) in 1998.8 Although sensitive for the identification of persons with chronic HCV infection, risk-based screening failed to identify the majority of individuals with HCV infection due to both clinician and patient barriers.9-12 Analysis of the 2003-2010 National Health and Nutrition Examination Survey prevalence data demonstrated that approximately three fourths of individuals with chronic hepatitis C in the United States belonged to the 1945-1965 birth cohort.13 Based on these data, both the CDC and the US Preventive Services Task Force (USPSTF) recommended one-time hepatitis C sc
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
Hematological Problems in Pediatric Intensive Care
Revel-Vilk, S., Cox, P., Robitaille, N., & Blanchette, V. (2014) · Pediatric and Adolescent Medicine · doi:10.1159/000350346 · Cited by 3,508
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
Bedossa, P., Dargère, D., & Paradis, V. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.022 · Cited by 2,376
Garcia‐Tsao, G., Abraldes, J. G., Berzigotti, A., & Bosch, J. (2017) · Hepatology · doi:10.1002/hep.28906 · Cited by 2,154
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
Regev, A., Berho, M. E., Jeffers, L. J., Milikowski, C., Molina, E. G., Pyrsopoulos, N., Feng, Z.-Z., Reddy, K. R., & Schiff, E. R. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04396-4 · Cited by 2,093
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Rockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C., & Smith, A. D. (2009) · Hepatology · doi:10.1002/hep.22742 · Cited by 1,997
Global epidemiology and genotype distribution of the hepatitis C virus infection
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.027 · Cited by 1,903
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
The Natural History of Community-Acquired Hepatitis C in the United States
Alter, M. J., Margolis, H. S., Krawczynski, K., Judson, F. N., Mares, A., Alexander, W. J., Hu, P. Y., Miller, J. K., Gerber, M. A., Sampliner, R. E., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272702 · Cited by 1,592
van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Panel, A. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,382
Self-citationLiver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., et al. (1999) · Hepatology · doi:10.1002/hep.510300409 · Cited by 1,219
(1998) · PsycEXTRA Dataset · doi:10.1037/e547602006-001 · Cited by 1,213
Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M., & Albrecht, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.33023 · Cited by 1,146
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P. J., Gruener, N., Abergel, A., Mangia, A., Lai, C.-L., Chan, H. L. Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512610 · Cited by 1,106
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
Smith, B. D., Morgan, R. L., Beckett, G. A., Falck-Ytter, Y. T., Holtzman, D. J., Teo, C., Jewett, A., Baack, B. N., Rein, D. B., Patel, N., et al. (2012) · PubMed · Cited by 991
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., Lawitz, E., Thompson, A., Shiffman, M. L., Cooper, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512612 · Cited by 846
Morgan, R. L., Baack, B., Smith, B. D., Yartel, A., Pitasi, M., & Falck-Ytter, Y. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-5-201303050-00005 · Cited by 829
Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016.
Seth, P., Scholl, L., Rudd, R. A., & Bacon, S. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6712a1 · Cited by 821
Hermine, O., Lefrère, F., Bronowicki, J.-P., Mariette, X., Jondeau, K., Eclache-Saudreau, V., Delmas, B., Valensi, F., Cacoub, P., Brechot, C., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013376 · Cited by 807
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., Illeperuma, A., Svarovskaia, E., Brainard, D. M., Symonds, W. T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316145 · Cited by 795
Hepatitis C: the clinical spectrum of disease.
Hoofnagle, J. H. (1997) · Hepatology · doi:10.1002/hep.510260703 · Cited by 765 · cited 2×
“HCV RNA typically becomes reliably detectable within 2-3 weeks after viral exposure(306-309); HCV antibody seroconversion among immunocompetent persons typically occurs 2-3 months after exposure, on average.”
BackgroundHassan, M. M., Hwang, L.-Y., Hatten, C. J., Swaim, M., Li, D., Abbruzzese, J. L., Beasley, P., & Patt, Y. Z. (2002) · Hepatology · doi:10.1053/jhep.2002.36780 · Cited by 762
Denniston, M. M., Jiles, R. B., Drobeniuc, J., Klevens, R. M., Ward, J. W., McQuillan, G. M., & Holmberg, S. D. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1133 · Cited by 724
Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression
Hui, J. M., Sud, A., Farrell, G. C., Bandara, P., Byth, K., Kench, J. G., McCaughan, G. W., & George, J. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.08.032 · Cited by 718
Whitlock, E. P., Polen, M. R., Green, C. A., Orleans, T., & Klein, J. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00017 · Cited by 717
Panel, A.-I. H. G., Chung, R. T., Ghany, M. G., Kim, A. Y., Marks, K. M., Naggie, S., Vargas, H. E., Aronsohn, A. I., Bhattacharya, D., Broder, T., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy585 · Cited by 717
Self-citationZibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B., Iqbal, K., Ward, J. W., & Holtzman, D. (2018) · American Journal of Public Health · doi:10.2105/ajph.2017.304132 · Cited by 698
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2575 · Cited by 688
(2013) · American Journal of Transplantation · doi:10.1111/ajt.12073 · Cited by 687
Sangiovanni, A., Prati, G. M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., Del Ninno, E., Morabito, A., & Colombo, M. (2006) · Hepatology · doi:10.1002/hep.21176 · Cited by 628
Carrat, F., Fontaine, H., Dorival, C., Simony, M., Diallo, A., Hezode, C., De Ledinghen, V., Larrey, D., Haour, G., Bronowicki, J.-P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32111-1 · Cited by 628
Mohaghegh, H. (2014) · Journal of Liver · doi:10.4172/2167-0889.1000147 · Cited by 609
Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C
Castera, L. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.017 · Cited by 605
Veldt, B. J., Heathcote, E. J., Wedemeyer, H., Reichen, J., Hofmann, W. P., Zeuzem, S., Manns, M. P., Hansen, B. E., Schalm, S. W., & Janssen, H. L. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-10-200711200-00003 · Cited by 602
Ioannou, G. N., Green, P. K., & Berry, K. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.08.030 · Cited by 573
Moucari, R., Asselah, T., Cazals–Hatem, D., Voitot, H., Boyer, N., Ripault, M., Sobesky, R., Martinot–Peignoux, M., Maylin, S., Nicolas–Chanoine, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.010 · Cited by 546
Nahon, P., Bourcier, V., Layese, R., Audureau, E., Cagnot, C., Marcellin, P., Guyader, D., Fontaine, H., Larrey, D., De Lédinghen, V., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.009 · Cited by 538
Suryaprasad, A. G., White, J. Z., Xu, F., Eichler, B.-A., Hamilton, J., Patel, A., Hamdounia, S. B., Church, D. R., Barton, K., Fisher, C., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu643 · Cited by 500
Aberg, J. A., Gallant, J. E., Ghanem, K. G., Emmanuel, P., Zingman, B. S., & Horberg, M. A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit665 · Cited by 496
Vogt, M. O., Lang, T., Frösner, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411202 · Cited by 488
Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., et al. (2013) · Hepatology · doi:10.1002/hep.26431 · Cited by 488
A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C
Backus, L. I., Boothroyd, D. B., Phillips, B. R., Belperio, P., Halloran, J., & Mole, L. A. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.004 · Cited by 481
Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶
Morgan, T. R., Ghany, M. G., Kim, H.-Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., Lee, W. M., Di Bisceglie, A. M., Bonkovsky, H. L., Dienstag, J. L., et al. (2010) · Hepatology · doi:10.1002/hep.23744 · Cited by 479
Self-citationVertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis
Benova, L., Mohamoud, Y. A., Calvert, C., & Abu-Raddad, L. J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu447 · Cited by 479
Moyer, V. A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-5-201309030-00672 · Cited by 475
Persistence of Viremia and the Importance of Long–Term Follow–Up After Acute Hepatitis C Infection
Villano, S. A., Vlahov, D., Nelson, K. E., Cohn, S., & Thomas, D. L. (1999) · Hepatology · doi:10.1002/hep.510290311 · Cited by 475
Shiffman, R. N., Shekelle, P., Overhage, J. M., Slutsky, J., Grimshaw, J., & Deshpande, A. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-6-200309160-00013 · Cited by 451
Wiesner, R. H., Sorrell, M., & Villamil, F. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50268 · Cited by 442
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., Asselah, T., Bourlière, M., Ruane, P. J., Wedemeyer, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1702417 · Cited by 439
Impact of alcohol on the histological and clinical progression of Hepatitis C infection
Wiley, T. E., McCarthy, M., Breidi, L., McCarthy, M., & Layden, T. J. (1998) · Hepatology · doi:10.1002/hep.510280330 · Cited by 436
Thein, H.-H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008) · AIDS · doi:10.1097/qad.0b013e32830e6d51 · Cited by 409
Mast, E. E., Hwang, L., Seto, D. S. Y., Nolte, F. S., Nainan, O. V., Wurtzel, H., & Alter, M. J. (2005) · The Journal of Infectious Diseases · doi:10.1086/497701 · Cited by 396
Grebely, J., Page, K., Sacks-Davis, R., van der Loeff, M. S., Rice, T. M., Bruneau, J., Morris, M. D., Hajarizadeh, B., Amin, J., Cox, A. L., et al. (2014) · Hepatology · doi:10.1002/hep.26639 · Cited by 388
Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.52 · Cited by 387
Denniston, M. M., Klevens, M. R., McQuillan, G. M., & Jiles, R. B. (2012) · Hepatology · doi:10.1002/hep.25556 · Cited by 378
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C
Fartoux, L., Poujol-Robert, A., Guéchot, J., Wendum, D., Poupon, R., & Serfaty, L. (2005) · Gut · doi:10.1136/gut.2004.050302 · Cited by 375
Characteristics of patients with dual infection by hepatitis B and C viruses
Zarski, J.-P., Bohn, B., Bastie, A., Pawlotsky, J.-M., Baud, M., Bost-Bezeaux, F., van Nhieu, J. T., Seigneurin, J.-M., Buffet, C., & Dhumeaux, D. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80198-0 · Cited by 374
Chou, R., & Wasson, N. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00005 · Cited by 370
Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients
Goldberg, D. S., Abt, P. L., Blumberg, E. A., Van Deerlin, V. M., Levine, M., Reddy, K. R., Bloom, R. D., Nazarian, S. M., Sawinski, D., Porrett, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705221 · Cited by 364
Dore, G. J., Altice, F., Litwin, A. H., Dalgard, O., Gane, E. J., Shibolet, O., Luetkemeyer, A., Nahass, R., Peng, C.-Y., Conway, B., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0816 · Cited by 359
Noninvasive Measures of Liver Fibrosis
Rockey, D. C., & Bissell, M. D. (2006) · Hepatology · doi:10.1002/hep.21046 · Cited by 349
Forns, X., Lee, S. S., Valdes, J., Lens, S., Ghalib, R., Aguilar, H., Felizarta, F., Hassanein, T., Hinrichsen, H., Rincon, D., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30496-6 · Cited by 343
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients
Woolley, A. E., Singh, S. K., Goldberg, H. J., Mallidi, H. R., Givertz, M. M., Mehra, M. R., Coppolino, A., Kusztos, A. E., Johnson, M. E., Chen, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812406 · Cited by 335
Levitsky, J., Formica, R. N., Bloom, R. D., Charlton, M., Curry, M., Friedewald, J., Friedman, J., Goldberg, D., Hall, S., Ison, M., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14381 · Cited by 327
Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians
Getchell, J. P., Wroblewski, K., DeMaria, A., et al. (2013) · PubMed Central · Cited by 325
Corrao, G., & Aricò, S. (1998) · Hepatology · doi:10.1002/hep.510270404 · Cited by 324
Alter, M. J., Kuhnert, W. L., & Finelli, L. (2003) · PubMed · Cited by 320
Use and interpretation of virological tests for hepatitis C
Pawlotsky, J.-M. (2002) · Hepatology · doi:10.1053/jhep.2002.36815 · Cited by 320
van de Laar, T., Pybus, O., Bruisten, S., Brown, D., Nelson, M., Bhagani, S., Vogel, M., Baumgarten, A., Chaix, M.-L., Fisher, M., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.006 · Cited by 315
Martin, N. K., Hickman, M., Hutchinson, S. J., Goldberg, D. J., & Vickerman, P. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit296 · Cited by 314
Simmons, B., Saleem, J., Hill, A., Riley, R. D., & Cooke, G. S. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ948 · Cited by 314
Kwo, P. Y., Poordad, F., Asatryan, A., Wang, S., Wyles, D. L., Hassanein, T., Felizarta, F., Sulkowski, M. S., Gane, E., Maliakkal, B., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.039 · Cited by 302
Durand, C. M., Bowring, M. G., Brown, D. M., Chattergoon, M. A., Massaccesi, G., Bair, N., Wesson, R., Reyad, A., Naqvi, F. F., Ostrander, D., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2871 · Cited by 302
Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C
Mallet, V., Gilgenkrantz, H., Serpaggi, J., Verkarre, V., Vallet-Pichard, A., Fontaine, H., & Pol, S. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00006 · Cited by 299
Mandorfer, M., Kozbial, K., Schwabl, P., Freissmuth, C., Schwarzer, R., Stern, R., Chromy, D., Stättermayer, A. F., Reiberger, T., Beinhardt, S., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.027 · Cited by 299
Grebely, J., Dalgard, O., Conway, B., Cunningham, E. B., Bruggmann, P., Hajarizadeh, B., Amin, J., Bruneau, J., Hellard, M., Litwin, A. H., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30404-1 · Cited by 291
Page, K., Hahn, J. A., Evans, J., Shiboski, S., Lum, P., Delwart, E., Tobler, L., Andrews, W., Avanesyan, L., Cooper, S., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/605947 · Cited by 285
Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic.
Urbanus, A. T., van de Laar, T. J., Stolte, I. G., Schinkel, J., Heijman, T., Coutinho, R. A., & Prins, M. (2009) · AIDS · doi:10.1097/qad.0b013e32832e5631 · Cited by 276
Aberg, J. A., Gallant, J. E., Ghanem, K. G., Emmanuel, P., Zingman, B. S., & Horberg, M. A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit757 · Cited by 268
Simmons, B., Saleem, J., Heath, K., Cooke, G. S., & Hill, A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ396 · Cited by 261
Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct‐acting antiviral agents
Sise, M. E., Bloom, A. K., Wisocky, J., Lin, M. V., Gustafson, J. L., Lundquist, A. L., Steele, D., Thiim, M., Williams, W. W., Hashemi, N., et al. (2016) · Hepatology · doi:10.1002/hep.28297 · Cited by 261
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Sulkowski, M. S., Naggie, S., Lalezari, J., Fessel, W. J., Mounzer, K., Shuhart, M., Luetkemeyer, A. F., Asmuth, D., Gaggar, A., Ni, L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7734 · Cited by 254
Bellentani, S., Pozzato, G., Saccoccio, G., Crovatto, M., Crocè, L. S., Mazzoran, L., Masutti, F., Cristianini, G., & Tiribelli, C. (1999) · Gut · doi:10.1136/gut.44.6.874 · Cited by 246
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic.
Wandeler, G., Gsponer, T., Bregenzer, A., Günthard, H. F., Clerc, O., Calmy, A., Stöckle, M., Bernasconi, E., Furrer, H., & Rauch, A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis694 · Cited by 241 · cited 1×
“Because of the high incidence and prevalence of HCV infection in these populations,(39-47) at least annual HCV testing is recommended.”
BackgroundJacobson, I. M., Lawitz, E., Gane, E. J., Willems, B. E., Ruane, P. J., Nahass, R. G., Borgia, S. M., Shafran, S. D., Workowski, K. A., Pearlman, B., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.047 · Cited by 239
Nahon, P., Layese, R., Bourcier, V., Cagnot, C., Marcellin, P., Guyader, D., Pol, S., Larrey, D., De Lédinghen, V., Ouzan, D., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.015 · Cited by 235
Seem, D. L., Lee, I., Umscheid, C. A., & Kuehnert, M. J. (2013) · Public Health Reports® · doi:10.1177/003335491312800403 · Cited by 234
Asselah, T., Kowdley, K. V., Zadeikis, N., Wang, S., Hassanein, T., Horsmans, Y., Colombo, M. G., Calinas, F., Aguilar, H. I., de Lédinghen, V., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.09.027 · Cited by 233
Prospective Evaluation of Community‐Acquired Acute‐Phase Hepatitis C Virus Infection
Cox, A. L., Netski, D. M., Mosbruger, T., Sherman, S. G., Strathdee, S., Ompad, D., Vlahov, D., Chien, D., Shyamala, V., Ray, S. C., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/428578 · Cited by 231
European Paediatric Hepatitis C Virus Network (2005) · The Journal of Infectious Diseases · doi:10.1086/497695 · Cited by 229
Hagan, H., Jordan, A. E., Neurer, J., & Cleland, C. M. (2015) · AIDS · doi:10.1097/qad.0000000000000834 · Cited by 228
Reese, P. P., Abt, P. L., Blumberg, E. A., Van Deerlin, V. M., Bloom, R. D., Potluri, V. S., Levine, M., Porrett, P., Sawinski, D., Nazarian, S. M., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0749 · Cited by 226
Dynamics of viremia in early hepatitis C virus infection
Glynn, S. A., Wright, D. J., Kleinman, S. H., Hirschkorn, D., Tu, Y., Heldebrant, C., Smith, R., Giachetti, C., Gallarda, J., & Busch, M. P. (2005) · Transfusion · doi:10.1111/j.1537-2995.2005.04390.x · Cited by 217
D'Souza, R., Sabin, C. A., & Foster, G. R. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41403.x · Cited by 212
Gragnani, L., Visentini, M., Fognani, E., Urraro, T., De Santis, A., Petraccia, L., Perez, M., Ceccotti, G., Colantuono, S., Mitrevski, M., et al. (2016) · Hepatology · doi:10.1002/hep.28753 · Cited by 211
Kumar, S., Deleve, L. D., Kamath, P. S., & Tefferi, A. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.5.589 · Cited by 200
Institute of Medicine Recommendations for the Prevention and Control of Hepatitis B and C
Mitchell, A. E., Colvin, H. M., & Beasley, P. R. (2010) · Hepatology · doi:10.1002/hep.23561 · Cited by 195
Cottrell, E. B., Chou, R., Wasson, N., Rahman, B., & Guise, J.-M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-2-201301150-00575 · Cited by 194
Harris, D. R., Gonin, R., Alter, H. J., Wright, E. C., Buskell, Z. J., Hollinger, F. B., Seeff, L. B., & for the National Heart, L. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00012 · Cited by 194
Mack, C. L., Gonzalez‐Peralta, R. P., Gupta, N., Leung, D., Narkewicz, M. R., Roberts, E. A., Rosenthal, P., & Schwarz, K. B. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318258328d · Cited by 193
Three Broad Modalities in the Natural History of Vertically Acquired Hepatitis C Virus Infection
The European Paediatric Hepatitis C Virus Network (2005) · Clinical Infectious Diseases · doi:10.1086/430601 · Cited by 193
Balistreri, W. F., Murray, K. F., Rosenthal, P., Bansal, S., Lin, C., Kersey, K., Massetto, B., Zhu, Y., Kanwar, B., German, P., et al. (2017) · Hepatology · doi:10.1002/hep.28995 · Cited by 191
Jara, P., Resti, M., Hierro, L., Giacchino, R., Barbera, C., Zancan, L., Crivellaro, C., Sokal, E., Azzari, C., Guido, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/345908 · Cited by 190
Hepatitis C Virus–Associated Fulminant Hepatic Failure
Farci, P., Alter, H. J., Shimoda, A., Govindarajan, S., Cheung, L. C., Melpolder, J. C., Sacher, R. A., Shih, J. W., & Purcell, R. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350904 · Cited by 189
Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV
Thomson, E. C., Nastouli, E., Main, J., Karayiannis, P., Eliahoo, J., Muir, D., & McClure, M. O. (2009) · AIDS · doi:10.1097/qad.0b013e32831940a3 · Cited by 186
Bersoff-Matcha, S. J., Cao, K., Jason, M., Ajao, A., Jones, S. C., Meyer, T., & Brinker, A. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0377 · Cited by 186
Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C
Barrera, J. M., Bruguera, M., Ercilla, G. M., Gil, C., Celis, R., Gil, P. M., Del Onorato, V. M., Rodés, J., & Ordinas, A. (1995) · Hepatology · doi:10.1002/hep.1840210306 · Cited by 185
Younossi, Z., & Henry, L. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13090 · Cited by 182
Hepatitis C virus infection in children and adolescents
Indolfi, G., Easterbrook, P., Dusheiko, G., El-Sayed, M. H., Jonas, M. M., Thorne, C., Bulterys, M., Siberry, G., Walsh, N., Chang, M.-H., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30046-9 · Cited by 182
Acute Hepatitis C: A Systematic Review.: CME
Kamal, S. M. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01825.x · Cited by 180
Petta, S., Cammà, C., Marco, V. D., Alessi, N., Cabibi, D., Caldarella, R., Licata, A., Massenti, F., Tarantino, G., Marchesini, G., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01813.x · Cited by 179
Arcaini, L., Besson, C., Frigeni, M., Fontaine, H., Goldaniga, M., Casato, M., Visentini, M., Torres, H. A., Loustaud-Ratti, V., Peveling-Oberhag, J., et al. (2016) · Blood · doi:10.1182/blood-2016-05-714667 · Cited by 179
Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006
Williams, I. T., Bell, B. P., Kuhnert, W., & Alter, M. J. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.511 · Cited by 175
Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016
Rosenberg, E. S., Rosenthal, E. M., Hall, E. W., Barker, L., Hofmeister, M. G., Sullivan, P. S., Dietz, P., Mermin, J., & Ryerson, A. B. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6371 · Cited by 175
Mücke, M. M., Backus, L. I., Mücke, V. T., Coppola, N., Preda, C. M., Yeh, M.-L., Tang, L. S. Y., Belperio, P. S., Wilson, E. M., Yu, M.-L., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30002-5 · Cited by 174
Marcellin, P., Pequignot, F., Delarocque-Astagneau, E., Zarski, J.-P., Ganne, N., Hillon, P., Antona, D., Bovet, M., Mechain, M., Asselah, T., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.09.010 · Cited by 172
Boerekamps, A., van den Berk, G. E., Lauw, F. N., Leyten, E. M., van Kasteren, M. E., van Eeden, A., Posthouwer, D., Claassen, M. A., Dofferhoff, A. S., Verhagen, D. W. M., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1007 · Cited by 171
Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons
He, T., Li, K., Roberts, M. S., Spaulding, A. C., Ayer, T., Grefenstette, J. J., & Chhatwal, J. (2016) · Annals of Internal Medicine · doi:10.7326/m15-0617 · Cited by 167
Saxena, V., Khungar, V., Verna, E. C., Levitsky, J., Brown, R. S., Hassan, M. A., Sulkowski, M. S., O'Leary, J. G., Koraishy, F., Galati, J. S., et al. (2017) · Hepatology · doi:10.1002/hep.29258 · Cited by 167
Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients
MUZZI, A., LEANDRO, G., RUBBIABRANDT, L., JAMES, R., KEISER, O., MALINVERNI, R., DUFOUR, J., HELBLING, B., HADENGUE, A., & GONVERS, J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.022 · Cited by 165
Younossi, Z. M., Stepanova, M., Afdhal, N., Kowdley, K. V., Zeuzem, S., Henry, L., Hunt, S. L., & Marcellin, P. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.014 · Cited by 164
Chen, G., Wang, C., Chen, J., Ji, D., Wang, Y., Wu, V., Karlberg, J., & Lau, G. (2017) · Hepatology · doi:10.1002/hep.29109 · Cited by 164
Casiraghi, M. A., De Paschale, M., Romanò, L., Biffi, R., Assi, A., Binelli, G., & Zanetti, A. R. (2004) · Hepatology · doi:10.1002/hep.20030 · Cited by 160
Bugianesi, E., Marchesini, G., Gentilcore, E., et al. (2006) · Hepatology · doi:10.1002/hep.21429 · Cited by 155
Ly, K. N., Jiles, R. B., Teshale, E. H., Foster, M. A., Pesano, R. L., & Holmberg, S. D. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2350 · Cited by 152
Poynard, T., Moussalli, J., Munteanu, M., Thabut, D., Lebray, P., Rudler, M., Ngo, Y., Thibault, V., M’Kada, H., Charlotte, F., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.015 · Cited by 151
Read, P. J., Lothian, R., Chronister, K. J., Gilliver, R., Kearley, J., Dore, G. J., & van Beek, I. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.05.032 · Cited by 149
Rockstroh, J. K., Lacombe, K., Viani, R. M., Orkin, C. M., Wyles, D. L., Luetkemeyer, A. F., Soto-Malave, R., Flisiak, R., Bhagani, S. R., Sherman, K. E., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy220 · Cited by 148
Safdar, K., & Schiff, E. R. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-832942 · Cited by 147
Clinical features and progression of perinatally acquired hepatitis C virus infection
Resti, M., Jara, P., Hierro, L., Azzari, C., Giacchino, R., Zuin, G., Zancan, L., Pedditzi, S., & Bortolotti, F. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10405 · Cited by 145
Testing for HCV infection: an update of guidance for clinicians and laboratorians.
(2013) · PubMed · Cited by 145
Westin, J., Lagging, M., Spak, F., Aires, N., Svensson, E., Lindh, M., Dhillon, A. P., Norkrans, G., & Wejstål, R. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00356.x · Cited by 144
Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C
Minola, E., Prati, D., Suter, F., Maggiolo, F., Caprioli, F., Sonzogni, A., Fraquelli, M., Paggi, S., & Conte, D. (2002) · Blood · doi:10.1182/blood-2001-12-0192 · Cited by 143
Sexually acquired hepatitis C virus infection: a review
Chan, D. P. C., Sun, H., Wong, H. T. H., Lee, S. S., & Hung, C. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.05.030 · Cited by 140
Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors
Kwong, A. J., Wall, A. E., Melcher, M. L., Wang, U., Ahmed, A., Subramanian, A. K., & Kwo, P. Y. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15162 · Cited by 140
Barocas, J. A., Brennan, M. B., Hull, S. J., Stokes, S., Fangman, J. J. W., & Westergaard, R. P. (2014) · Harm Reduction Journal · doi:10.1186/1477-7517-11-1 · Cited by 138
Koneru, A., Nelson, N. P., Hariri, S., Canary, L., Sanders, K. J., Maxwell, J. F., Huang, X., Leake, J. A. D., Ward, J. W., & Vellozzi, C. J. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6528a2 · Cited by 138
Acute hepatitis C virus infection: A chronic problem
Blackard, J. T., Shata, M. T. M., Shire, N. J., & Sherman, K. E. (2007) · Hepatology · doi:10.1002/hep.21902 · Cited by 136
Utilization of FibroScan in Clinical Practice
Bonder, A., & Afdhal, N. H. (2014) · Current Gastroenterology Reports · doi:10.1007/s11894-014-0372-6 · Cited by 135
Martin, N. K., Thornton, A., Hickman, M., Sabin, C. A., Nelson, M. R., Cooke, G., Martin, T., Delpech, V., Ruf, M., Price, H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw075 · Cited by 135
D’Ambrosio, R., PASULO, L., Puoti, M., Vinci, M. R., Schiavini, M., Lazzaroni, S., Soria, A., Gatti, F., Menzaghi, B., Aghemo, A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.11.011 · Cited by 133
Witt, M. D., Seaberg, E. C., Darilay, A. T., Young, S., Badri, S. M., Rinaldo, C. R., Jacobson, L. P., Detels, R., & Thio, C. L. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit197 · Cited by 132
Molnar, M. Z., Nair, S. P., Cseprekál, O., Yazawa, M., Talwar, M., Balaraman, V., Podila, P. S. B., Mas, V. R., Maluf, D. G., Helmick, R. A., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15530 · Cited by 130
Deterding, K., Spinner, C. D., Schott, E., Welzel, T. M., Gerken, G., Klinker, H., Spengler, U., Wiegand, J., Wiesch, J. S. Z., Pathil, A., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30408-x · Cited by 129
Hepatocellular Carcinoma in 2 Young Adolescents With Chronic Hepatitis C
González‐Peralta, R. P., Langham, M. R., Andres, J. M., Mohan, P., Colombani, P. M., Alford, M. K., & Schwarz, K. B. (2009) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318170af04 · Cited by 127
Norton, B. L., Fleming, J. G., Bachhuber, M. A., Steinman, M., DeLuca, J., Cunningham, C. O., Johnson, N., Laraque, F., & Litwin, A. H. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.07.021 · Cited by 126
Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users
Chamot, E., Hirschel, B. J., Wintsch, J., Robert, C.-F., Gabriel, V., Déglon, J., Yerly, S., & Perrin, L. H. (1990) · AIDS · doi:10.1097/00002030-199012000-00016 · Cited by 124
Fierer, D. S., Uriel, A. J., Carriero, D., Klepper, A. L., Dieterich, D. T., Mullen, M. P., Thung, S. N., Fiel, M. I., & Branch, A. D. (2008) · The Journal of Infectious Diseases · doi:10.1086/590430 · Cited by 119
Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C Virus–Infected Women
Kuncio, D. E., Newbern, E. C., Johnson, C. C., & Viner, K. M. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw026 · Cited by 118
Cypel, M., Feld, J. J., Galasso, M., Ribeiro, R. V. P., Marks, N., Kuczynski, M., Kumar, D., Bahinskaya, I., Bagnato, V. S., Kurachi, C., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30268-1 · Cited by 118
Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C
Cua, I. H. Y., Hui, J. M., Kench, J. G., & George, J. (2008) · Hepatology · doi:10.1002/hep.22392 · Cited by 117
Murray, K. F., Balistreri, W. F., Bansal, S., Whitworth, S., Evans, H., González‐Peralta, R. P., Wen, J. W., Massetto, B., Kersey, K., Shao, J., et al. (2018) · Hepatology · doi:10.1002/hep.30123 · Cited by 112
Lee, S. R., Kardos, K. W., Schiff, E. R., Berne, C. A., Mounzer, K., Banks, A. T., Tatum, H. A., Friel, T. J., DeMicco, M. P., Lee, W. M., et al. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.12.009 · Cited by 111
Spontaneous clearance of childhood hepatitis C virus infection
Yeung, L., To, T. M., King, S., & Roberts, E. A. (2007) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2007.00873.x · Cited by 110
Younossi, Z. M., Stepanova, M., Feld, J. J., Zeuzem, S., Jacobson, I. M., Agarwal, K., Hézode, C., Nader, F., Henry, L. L., & Hunt, S. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.042 · Cited by 109
Lange, B., Roberts, T., Cohn, J., Greenman, J., Camp, J., Ishizaki, A., Messac, L., Tuaillon, É., de Perre, P. V., Pichler, C., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2776-z · Cited by 107
Pathology of chronic hepatitis C in children
Kage, M., Fujisawa, T., Shiraki, K., Tanaka, T., Kimura, A., Shimamatsu, K., Nakashima, E., Kojiro, M., Koike, M., Tazawa, Y., et al. (1997) · Hepatology · doi:10.1002/hep.510260333 · Cited by 106
Schiano, T. D., Azeem, S., Bodian, C., Bodenheimer, H. C., Merati, S., Thung, S. N., & Hytiroglou, P. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00541-0 · Cited by 105
Strathdee, S. A., Latka, M. H., Campbell, J. V., O’Driscoll, P. T., Golub, E. T., Kapadia, F., Pollini, R. A., Garfein, R. S., Thomas, D. L., Hagan, H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/427445 · Cited by 105
Wirth, S., Rosenthal, P. J., González‐Peralta, R. P., Jonas, M. M., Balistreri, W. F., Lin, C., Hardikar, W., Kersey, K., Massetto, B., Kanwar, B., et al. (2017) · Hepatology · doi:10.1002/hep.29278 · Cited by 105
Litwin, A. H., Harris, K. A., Nahvi, S., et al. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2008.09.009 · Cited by 104
Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C
Coffin, P. O., Scott, J. D., Golden, M. R., & Sullivan, S. D. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis011 · Cited by 104
Janjua, N. Z., Chong, M., Kuo, M. E., Woods, R. R., Wong, J., Yoshida, E. M., Sherman, M., Butt, Z. A., Samji, H., Cook, D. A., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.028 · Cited by 103
Nijmeijer, B. M., Koopsen, J., Schinkel, J., Prins, M., & Geijtenbeek, T. B. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25348 · Cited by 100
Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria
McGovern, B., Birch, C. E., Bowen, M. J., Reyor, L. L., Nagami, E. H., Chung, R. T., & Kim, A. Y. (2009) · Clinical Infectious Diseases · doi:10.1086/605561 · Cited by 99
Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C
Schwarz, K. B., Rosenthal, P. J., Murray, K. F., Honegger, J. R., Hardikar, W., Hague, R., Mittal, N. K., Massetto, B., Brainard, D. M., Hsueh, C., et al. (2019) · Hepatology · doi:10.1002/hep.30830 · Cited by 99
Petta, S., Cammà, C., Marco, V. D., Macaluso, F. S., Maida, M. F., Pizzolanti, G., Belmonte, B., Cabibi, D., Stefano, R. D., Ferraro, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02453.x · Cited by 95
Younossi, Z. M., Stepanova, M., Henry, L. L., Gane, E. J., Jacobson, I. M., Lawitz, E., Nelson, D. R., Gerber, L. H., Nader, F., & Hunt, S. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.11.032 · Cited by 93
Gupta, G., Yakubu, I., Bhati, C. S., Zhang, Y., Kang, L., Patterson, J. A., Andrews-Joseph, A., Alam, A., Ferreira‐Gonzalez, A., Kumar, D., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15664 · Cited by 92
Association Between Liver Fibrosis and Insulin Sensitivity in Chronic Hepatitis C Patients
Taura, N., Ichikawa, T., Hamasaki, K., Nakao, K., Nishimura, D., Goto, T., Fukuta, M., Kawashimo, H., Fujimoto, M., Kusumoto, K., et al. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00835.x · Cited by 90
Eckman, M. H., Ward, J. W., & Sherman, K. E. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.080 · Cited by 90
Kruse, R. L., Kramer, J. R., Tyson, G. L., Duan, Z., Chen, L., El‐Serag, H. B., & Kanwal, F. (2014) · Hepatology · doi:10.1002/hep.27337 · Cited by 86
Chronic Hepatitis C in Childhood: An 18-Year Experience
Iorio, R. F., Giannattasio, A., Sepe, A. O., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497141 · Cited by 83
Shebl, F. M., El‐Kamary, S. S., Saleh, D. A., Abdel‐Hamid, M., Mikhail, N. N. H., Allam, A. A.-H., El‐Arabi, H., Elhenawy, I. A., El-Kafrawy, S. A., El-Daly, M. M., et al. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21480 · Cited by 81
Assoumou, S. A., Tasillo, A., Leff, J. A., Schackman, B. R., Drainoni, M., Horsburgh, C. R., Barry, M. A., Regis, C., Kim, A. Y., Marshall, A. D., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix798 · Cited by 80
Iacono, O. L., Venezia, G., Petta, S., Mineo, C., LISI, S. D., Marco, V. D., Rodolico, V., Amato, M. C., Ferraro, D., Giordano, C. S. D. S., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03309.x · Cited by 79
Rockstroh, J. K., Bhagani, S. R., Hyland, R. H., Yun, C., Dvory‐Sobol, H., Zheng, W., Brainard, D. M., Ingiliz, P., Lutz, T., Boesecke, C., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30003-1 · Cited by 79
García‐Monzón, C., Jara, P., Fernández‐Bermejo, M., Hierro, L., Frauca, E., Camarena, C., Díaz, C., Vega, A. D. L., Larrauri, J., García-Iglesias, C., et al. (1998) · Hepatology · doi:10.1002/hep.510280633 · Cited by 77
Svegliati‐Baroni, G., Bugianesi, E., Bouserhal, T., Marini, F., Ridolfi, F., Tarsetti, F., Ancarani, F., Petrelli, E., Peruzzi, E., Cascio, M. L., et al. (2007) · Gut · doi:10.1136/gut.2006.107946 · Cited by 76
Boscarino, J. A., Lu, M., Moorman, A. C., Gordon, S. C., Rupp, L. B., Spradling, P. R., Teshale, E. H., Schmidt, M. A., Vijayadeva, V., Holmberg, S. D., et al. (2015) · Hepatology · doi:10.1002/hep.27422 · Cited by 75
Younossi, Z. M., Zheng, L., Stepanova, M., Venkatesan, C., & Mir, H. M. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12265 · Cited by 75
Cost-effectiveness of screening for hepatitis C in Canada
Wong, W. W. L., Tu, H.-A., Feld, J. J., Wong, T., & Krahn, M. D. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.140711 · Cited by 75
Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review.
Jin, F., Matthews, G. V., & Grulich, A. E. (2017) · Sexual Health · doi:10.1071/sh16141 · Cited by 74
Perinatal Transmission of Hepatitis C Virus: Defining the Cascade of Care
Epstein, R. L., Sabharwal, V., Wachman, E. M., Saia, K., Vellozzi, C. J., Hariri, S., & Linas, B. P. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.07.006 · Cited by 74
Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States
Chaillon, A., Rand, E. B., Reau, N. S., & Martin, N. K. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz063 · Cited by 74
Transmission of Hepatitis C Virus From Organ Donors Despite Nucleic Acid Test Screening
Suryaprasad, S., Basavaraju, S. V., Hocevar, S. N., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13283 · Cited by 72
Bruneau, J., Zang, G., Abrahamowicz, M., Jutras‐Aswad, D., Daniel, M., & Roy, É. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit938 · Cited by 72
Barocas, J. A., Tasillo, A., Yazdi, G. E., Wang, J., Vellozzi, C. J., Hariri, S., Isenhour, C. J., Randall, L. M., Ward, J. W., Mermin, J., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy098 · Cited by 72
Behairy, B. E., Sıra, M. M., Zalata, K., Salama, E. I., & Abd-Allah, M. A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i16.4238 · Cited by 71
Landau, D. A., Scerra, S., Sène, D., Resche‐Rigon, M., Saadoun, D., & Cacoub, P. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090790 · Cited by 69
Perinatal Transmission of Hepatitis C Virus
Indolfi, G., Azzari, C., & Resti, M. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.06.077 · Cited by 69
Research works printed but not linked: 125
- 2015, Comparison of risk‐based hepatitis C screening and the true seroprevalence in an urban prison system, J Urban Health, 92, 379, 10.1007/s11524-015-9945-4 · doi:10.1007/s11524-015-9945-4
- 2018, Healthcare value of implementing hepatitis C screening in the adult general population in Spain, PLoS One, 13
- 2016, Evaluation of the Centers for Disease Control and Prevention recommendations for hepatitis C virus testing in an urban emergency department, Clin Infect Dis, 62, 1059, 10.1093/cid/ciw074 · doi:10.1093/cid/ciw074
- 2016, Prevalence of diagnosed and undiagnosed hepatitis C in a midwestern urban emergency department, Clin Infect Dis, 62, 1066, 10.1093/cid/ciw073 · doi:10.1093/cid/ciw073
- 2015, High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes, J Epidemiol Community Health, 69, 599, 10.1136/jech-2014-205070 · doi:10.1136/jech-2014-205070
- 2012, HCV seroconversion among never‐injecting heroin users at baseline: no predictors identified other than starting injection, Int J Drug Policy, 23, 415, 10.1016/j.drugpo.2012.02.002 · doi:10.1016/j.drugpo.2012.02.002
- 2016, Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care, Clin Microbiol Infect, 22, 459.e1, 10.1016/j.cmi.2016.01.009 · doi:10.1016/j.cmi.2016.01.009
- 2016, Identification and clinical management of persons with chronic hepatitis C virus infection—Cherokee Nation, 2012‐2015, MMWR Morb Mortal Wkly Rep, 65, 461, 10.15585/mmwr.mm6518a2 · doi:10.15585/mmwr.mm6518a2
- 2008, Validation of a strategy for HCV antibody testing with two enzyme immunoassays in a routine clinical laboratory, J Clin Virol, 42, 394, 10.1016/j.jcv.2008.02.015 · doi:10.1016/j.jcv.2008.02.015
- 1996, Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma—its relationship to alcohol drinking and the age of transfusion, Alcohol Clin Exp Res, 20, 95A
- 2019, Liver stiffness assessed by ultrasound shear wave elastography from General Electric accurately predicts clinically significant portal hypertension in patients with advanced chronic liver disease, Ultraschall Med
- 2017, The negative impact of HBV/HCV coinfection on cirrhosis and its consequences, Aliment Pharmacol Ther, 46, 1054, 10.1111/apt.14352 · doi:10.1111/apt.14352
- 2019, Trends in treatment uptake and provider specialty for hepatitis C virus (HCV) infection in the Veterans Affairs healthcare system: results from the Electronically Retrieved Cohort of HCV‐Infected Veterans (ERCHIVES), Clin Infect Dis, 68, 857, 10.1093/cid/ciy697 · doi:10.1093/cid/ciy697
- 2017, Barriers to hepatitis C treatment in the era of direct‐acting anti‐viral agents, Aliment Pharmacol Ther, 46, 992, 10.1111/apt.14328 · doi:10.1111/apt.14328
- 2018, Differential effect of HCV eradication and fibrosis grade on hepatocellular carcinoma and all‐cause mortality, Sci Rep, 8, 12146
- 2018, Impact of sustained virologic response on short‐term clinical outcomes in hepatitis C–related cirrhosis, Eur J Gastroenterol Hepatol, 30, 296, 10.1097/MEG.0000000000001032 · doi:10.1097/meg.0000000000001032
- 2017, Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct‐acting antivirals, J Hepatol, 66, 1173, 10.1016/j.jhep.2017.01.020 · doi:10.1016/j.jhep.2017.01.020
- 2019, Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis, Clin Exp Med, 19, 1, 10.1007/s10238-018-0536-z · doi:10.1007/s10238-018-0536-z
- 2017, Direct‐acting antiviral agents in the therapy of hepatitis C virus–related mixed cryoglobulinaemia: a single‐centre experience, Arthritis Res Ther, 19, 74, 10.1186/s13075-017-1280-6 · doi:10.1186/s13075-017-1280-6
- 2019, Rapid regression of B‐cell non‐Hodgkin's lymphoma after eradication of hepatitis C virus by direct antiviral agents, Case Rep Gastroenterol, 13, 336, 10.1159/000501546 · doi:10.1159/000501546
- 2019, miRNA‐26b downregulation in peripheral blood mononuclear cells of patients with hepatitis C associated lymphomas is restored by successful interferon‐free antiviral therapy, Antivir Ther
- 2019, Lymphomas associated with chronic hepatitis C virus infection: a prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network, Hematol Oncol, 37, 160, 10.1002/hon.2575 · doi:10.1002/hon.2575
- 2012, Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection, Intern Med, 51, 2745, 10.2169/internalmedicine.51.8404 · doi:10.2169/internalmedicine.51.8404
- 2005, Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection, Aliment Pharmacol Ther, 21, 653, 10.1111/j.1365-2036.2005.02395.x · doi:10.1111/j.1365-2036.2005.02395.x
- 2005, Regression of advanced non‐splenic marginal zone lymphoma after treatment of hepatitis C virus infection, Leuk Lymphoma, 46, 1365, 10.1080/104281905001028289 · doi:10.1080/104281905001028289
- 2002, Regression of splenic lymphoma after treatment of hepatitis C virus infection, N Engl J Med, 347, 2168, 10.1056/NEJM200212263472614 · doi:10.1056/nejm200212263472614
- 2006, Improvement in quality of life measures in patients with refractory hepatitis C, responding to re‐treatment with pegylated interferon alpha ‐2b and ribavirin, Health Qual Life Outcomes, 4, 30, 10.1186/1477-7525-4-30 · doi:10.1186/1477-7525-4-30
- 2019, A systematic review and meta‐analysis of community and primary‐care‐based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments, BMC Health Serv Res, 19, 765, 10.1186/s12913-019-4635-7 · doi:10.1186/s12913-019-4635-7
- 2018, Direct‐acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment, Int J Drug Policy, 62, 74, 10.1016/j.drugpo.2018.10.003 · doi:10.1016/j.drugpo.2018.10.003
- 2017, Expansion of treatment for hepatitis C virus infection by task shifting to community‐based nonspecialist providers: a nonrandomized clinical trial, Ann Intern Med, 167, 311, 10.7326/M17-0118 · doi:10.7326/m17-0118
- 2018, Glucose metabolism changes in patients with chronic hepatitis C treated with direct acting antivirals, Can J Gastroenterol Hepatol, 2018, 6095097
- 2016, Rapid decline of fasting glucose in HCV diabetic patients treated with direct‐acting antiviral agents, Clin Microbiol Infect, 22, 462.e1, 10.1016/j.cmi.2015.12.030 · doi:10.1016/j.cmi.2015.12.030
- 2016, Hypoglycemia in a diabetic patient during hepatitis C therapy, Hepatology, 63, 2065, 10.1002/hep.28137 · doi:10.1002/hep.28137
- 2017, Reduction in warfarin effect associated with sofosbuvir–velpatasvir, Am J Health Syst Pharm, 74, 1308, 10.2146/ajhp170324 · doi:10.2146/ajhp170324
- 2019, Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older, PLoS One, 14
- 2019, Integrated analysis of 8‐week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection, J Gastroenterol, 54, 752, 10.1007/s00535-019-01569-7 · doi:10.1007/s00535-019-01569-7
- 2019, Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1‐6: results of the HCV‐Target Study [Abstract 956], Gastroenterology, 156, S1220
- 2018, Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis, J Gastroenterol, 53, 557, 10.1007/s00535-017-1391-5 · doi:10.1007/s00535-017-1391-5
- 2018, High SVR12 with 8‐week and 12‐week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1‐6 patients without cirrhosis, J Hepatol, 69, 293, 10.1016/j.jhep.2018.03.007 · doi:10.1016/j.jhep.2018.03.007
- 2019, Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase‐3, open‐label study in Russia and Sweden, Infect Dis (Lond), 51, 131, 10.1080/23744235.2018.1535186 · doi:10.1080/23744235.2018.1535186
- 2019, Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single‐arm, open‐label, phase 3 trial, Lancet Gastroenterol Hepatol, 4, 127, 10.1016/S2468-1253(18)30343-1 · doi:10.1016/s2468-1253(18)30343-1
- 2018, Resistance analysis in patients with genotype 1‐6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies, J Hepatol, 68, 895, 10.1016/j.jhep.2017.11.032 · doi:10.1016/j.jhep.2017.11.032
- 2019, Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry, Aliment Pharmacol Ther, 49, 1052, 10.1111/apt.15222 · doi:10.1111/apt.15222
- 2019, Effectiveness of therapy in 16,567 directly‐acting antiviral treated people in England: high response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis, J Hepatol, 70, e131, 10.1016/S0618-8278(19)30231-2 · doi:10.1016/s0618-8278(19)30231-2
- 2019, Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir, Aliment Pharmacol Ther, 49, 99, 10.1111/apt.15043 · doi:10.1111/apt.15043
- 2019, Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotype 6 in southwest China: real‐world experience of a retrospective study, J Viral Hepat, 26, 316, 10.1111/jvh.13033 · doi:10.1111/jvh.13033
- 2018, High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance‐associated substitutions in hepatitis C genotype 3 infection, Aliment Pharmacol Ther, 47, 1288, 10.1111/apt.14592 · doi:10.1111/apt.14592
- 2017, Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir‐based therapies, Clin Infect Dis, 64, 44, 10.1093/cid/ciw676 · doi:10.1093/cid/ciw676
- 2019, Glecaprevir/pibrentasvir for 8 weeks in treatment‐naive patients with chronic HCV genotypes 1‐6 and compensated cirrhosis: the EXPEDITION‐8 trial, J Hepatol
- 2016, 100% SVR4 with ABT‐493 and ABT‐530 with or without ribavirin in treatment‐naive HCV genotype 3‐infected patients with cirrhosis, J Hepatol, 64, S208, 10.1016/S0168-8278(16)00170-7 · doi:10.1016/s0168-8278(16)00170-7
- 2018, Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis, Gastroenterology, 155, 1120, 10.1053/j.gastro.2018.06.042 · doi:10.1053/j.gastro.2018.06.042
- 2018, Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis, Liver Int, 38, 443, 10.1111/liv.13534 · doi:10.1111/liv.13534
- 2019, Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: the MISTRAL study, Liver Int, 39, 1852, 10.1111/liv.14170 · doi:10.1111/liv.14170
- 2019, Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: results from a multicenter, real‐world cohort study, Hepatol Res, 49, 617, 10.1111/hepr.13328 · doi:10.1111/hepr.13328
- 2019, Real‐world experience of 12‐week DAA regimen of glecaprevir and pibrentasvir in patients with chronic HCV infection, J Gastroenterol Hepatol
- 2019, Real‐world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3, J Hepatol, 70, 15, 10.1016/j.jhep.2018.09.018 · doi:10.1016/j.jhep.2018.09.018
- 2019, A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype‐2 chronic infection, Eur J Gastroenterol Hepatol, 31, 382, 10.1097/MEG.0000000000001299 · doi:10.1097/meg.0000000000001299
- 2018, Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African‐American patients: a community‐based retrospective cohort study, Eur J Gastroenterol Hepatol, 30, 1200, 10.1097/MEG.0000000000001233 · doi:10.1097/meg.0000000000001233
- 2018, Satisfactory virological response and fibrosis improvement of sofosbuvir‐based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real‐world cohort study, Virol J, 15, 150, 10.1186/s12985-018-1066-8 · doi:10.1186/s12985-018-1066-8
- 2006, The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10‐year period, J Pediatr, 148, 353, 10.1016/j.jpeds.2005.10.031 · doi:10.1016/j.jpeds.2005.10.031
- 2015, Hepatitis C virus (HCV) vertical transmission in 12‐month‐old infants born to HCV‐infected women and assessment of maternal risk factors, Open Forum Infect Dis, 2, ofv089, 10.1093/ofid/ofv089 · doi:10.1093/ofid/ofv089
- 2001, Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV‐seronegative pregnant women: a 24‐month prospective study, J Pediatr Gastroenterol Nutr, 33, 570
- 2012, Anti‐HCV testing as a basic standard of monitoring HCV mother‐to‐child infection: advantages and disadvantages of the method, Przegl Epidemiol, 66, 341
- 2005, Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV‐infected mothers, Acta Paediatr, 94, 444, 10.1111/j.1651-2227.2005.tb01916.x · doi:10.1111/j.1651-2227.2005.tb01916.x
- 2012, Spontaneous clearance of hepatitis C virus in vertically infected children, Eur J Pediatr, 171, 253, 10.1007/s00431-011-1517-3 · doi:10.1007/s00431-011-1517-3
- 2016, Hepatitis C viraemia after apparent spontaneous clearance in a vertically infected child, Lancet, 387, 1967, 10.1016/S0140-6736(16)00085-4 · doi:10.1016/s0140-6736(16)00085-4
- 2018, Polymerase chain reaction (PCR) for detection of vertically acquired hepatitis C virus (HCV) infection in early infancy, Open Forum Infect Dis, 5, S654
- 2009, Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes, J Pediatr Gastroenterol Nutr, 48, 341, 10.1097/MPG.0b013e318185998f · doi:10.1097/mpg.0b013e318185998f
- 2008, Health‐related quality of life in children with hepatitis C acquired in the first year of life, J Gastroenterol Hepatol, 23, 226, 10.1111/j.1440-1746.2007.04859.x · doi:10.1111/j.1440-1746.2007.04859.x
- 2017, Clinical usefulness of new noninvasive serum biomarkers for the assessment of liver fibrosis and steatosis in children with chronic hepatitis C, Clin Exp Hepatol, 3, 198
- 2016, Transient liver elastography in unsedated control children: impact of age and intercurrent illness, J Paediatr Child Health, 52, 637, 10.1111/jpc.13151 · doi:10.1111/jpc.13151
- 2013, Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston Children's Hospital experience, J Pediatr, 163, 1058, 10.1016/j.jpeds.2013.04.044 · doi:10.1016/j.jpeds.2013.04.044
- 2018, Epidemiologic features of 348 children with hepatitis C virus infection over a 30‐year period: a nationwide survey in Japan, J Gastroenterol, 53, 419, 10.1007/s00535-017-1351-0 · doi:10.1007/s00535-017-1351-0
- 2008, Long‐term course of chronic hepatitis C in children: from viral clearance to end‐stage liver disease, Gastroenterology, 134, 1900, 10.1053/j.gastro.2008.02.082 · doi:10.1053/j.gastro.2008.02.082
- 2010, Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection, J Pediatr Gastroenterol Nutr, 51, 191, 10.1097/MPG.0b013e3181d32756 · doi:10.1097/mpg.0b013e3181d32756
- 2011, Diagnosis and management of hepatitis C virus–infected children, Pediatr Infect Dis J, 30, 983, 10.1097/INF.0b013e318236ac37 · doi:10.1097/inf.0b013e318236ac37
- 2008, Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds‐C Trial, Hepatology, 47, 836, 10.1002/hep.22094 · doi:10.1002/hep.22094
- 2006, Hepatitis C in children: a quaternary referral center perspective, J Pediatr Gastroenterol Nutr, 43, 209, 10.1097/01.mpg.0000228117.52229.32 · doi:10.1097/01.mpg.0000228117.52229.32
- 2015, Histopathology of hepatitis C in children, a systematic review: implications for treatment, Expert Rev Anti Infect Ther, 13, 1225, 10.1586/14787210.2015.1070668 · doi:10.1586/14787210.2015.1070668
- 2013, Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study, Hepatology, 58, 1580, 10.1002/hep.26519 · doi:10.1002/hep.26519
- 2004, The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort, Blood, 103, 2460, 10.1182/blood-2003-07-2565 · doi:10.1182/blood-2003-07-2565
- 1998, Histopathology of the liver in children with chronic hepatitis C viral infection, Hepatology, 28, 1416, 10.1002/hep.510280534 · doi:10.1002/hep.510280534
- 1998, Chronic hepatitis C in children: the pathological and clinical spectrum, Gastroenterology, 115, 1525, 10.1016/S0016-5085(98)70032-0 · doi:10.1016/s0016-5085(98)70032-0
- 2019, Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study, Hepatology
- 2017, Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment‐experienced patients with chronic hepatitis C infection, Gastroenterology, 152, 164, 10.1053/j.gastro.2016.09.045 · doi:10.1053/j.gastro.2016.09.045
- 2018, Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis, Liver Int, 38, 1583, 10.1111/liv.13727 · doi:10.1111/liv.13727
- 2018, Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial, Hepatology, 67, 514, 10.1002/hep.29541 · doi:10.1002/hep.29541
- 2019, Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9‐12 years) and adolescents, Hepatol Int, 13, 706, 10.1007/s12072-019-09985-w · doi:10.1007/s12072-019-09985-w
- 2018, Sustained viral response in genotype 4 chronic hepatitis C virus–infected children and adolescents treated with sofosbuvir/ledipasvir, J Pediatr Gastroenterol Nutr, 67, 626, 10.1097/MPG.0000000000002101 · doi:10.1097/mpg.0000000000002101
- 2011, The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes, Aliment Pharmacol Ther, 33, 559, 10.1111/j.1365-2036.2010.04549.x · doi:10.1111/j.1365-2036.2010.04549.x
- 2017, Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure, Transpl Infect Dis, 19
- 2015, Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study, PLoS One, 10
- 2014, Dynamics of HCV RNA levels during acute hepatitis C virus infection, J Med Virol, 86, 1722, 10.1002/jmv.24010 · doi:10.1002/jmv.24010
- 2018, Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis, Hepatology, 67, 837, 10.1002/hep.29611 · doi:10.1002/hep.29611
- 2012, Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA‐licensed assays: implications for transfusion safety and HCV infection outcomes, Blood, 119, 6326, 10.1182/blood-2011-12-393637 · doi:10.1182/blood-2011-12-393637
- 2015, Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes, J Hepatol, 63, 586, 10.1016/j.jhep.2015.04.025 · doi:10.1016/j.jhep.2015.04.025
- 2008, The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy, J Viral Hepat, 15, 120, 10.1111/j.1365-2893.2007.00900.x · doi:10.1111/j.1365-2893.2007.00900.x
- 2019, Ledipasvir/sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir‐containing regimens without iInterferon for treatment of acute HCV in HIV‐1 infected individuals, Clin Infect Dis
- 2019, Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)–viremic donors into HCV‐negative recipients: outcomes following liver transplant of HCV‐viremic donors, Hepatology, 69, 2381, 10.1002/hep.30540 · doi:10.1002/hep.30540
- 2016, Improving organ utilization to help overcome the tragedies of the opioid epidemic, Am J Transplant, 16, 2836, 10.1111/ajt.13971 · doi:10.1111/ajt.13971
- 2019, National trends in utilization and 1‐year outcomes with transplantation of HCV‐viremic kidneys, J Am Soc Nephrol, 30, 1939, 10.1681/ASN.2019050462 · doi:10.1681/asn.2019050462
- 2018, Changes in utilization and discard of HCV antibody–positive deceased donor kidneys in the era of direct‐acting antiviral therapy, Transplantation, 102, 2088, 10.1097/TP.0000000000002323 · doi:10.1097/tp.0000000000002323
- 2015, Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts, Transplantation, 99, 1192, 10.1097/TP.0000000000000479 · doi:10.1097/tp.0000000000000479
- 2018, Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney, Transpl Infect Dis, 20
- 2018, Hepatitis C transmission from seropositive, nonviremic donors to non‐hepatitis C liver transplant recipients, Hepatology, 67, 1673, 10.1002/hep.29704 · doi:10.1002/hep.29704
- 2019, Possible acute rejection associated with the use of the new anti–hepatitis C virus medications, Avicenna J Med, 9, 32, 10.4103/AJM.AJM_171_17 · doi:10.4103/ajm.ajm_171_17
- 2018, The impact of direct antiviral therapy for hepatitis C (DAA) on acute rejection and donor specific antibody formation in kidney transplant recipients, evidence from surveillance biopsies, Transplantation, 102, S325
- 2017, Efficacy and tolerability of interferon‐free antiviral therapy in kidney transplant recipients with chronic hepatitis C, J Hepatol, 66, 718, 10.1016/j.jhep.2016.12.020 · doi:10.1016/j.jhep.2016.12.020
- 2019, Impact of sofosbuvir‐based regimens for the treatment of hepatitis C after liver transplant on renal function: results of a Canadian national retrospective study, Exp Clin Transplant, 17, 59, 10.6002/ect.2017.0201 · doi:10.6002/ect.2017.0201
- 2018, Impact of anti‐HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid‐term follow‐up in a single‐center cohort study, Transpl Int, 31, 887, 10.1111/tri.13118 · doi:10.1111/tri.13118
- 2017, Direct‐acting antiviral agent‐based regimen for HCV recurrence after combined liver–kidney transplantation: results from the ANRS CO23 CUPILT study, Am J Transplant, 17, 2869, 10.1111/ajt.14490 · doi:10.1111/ajt.14490
- 2017, Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents, Transplantation, 101, 1704, 10.1097/TP.0000000000001618 · doi:10.1097/tp.0000000000001618
- 2019, Pre‐emptive pangenotypic direct acting antiviral therapy in donor HCV‐positive to recipient HCV‐negative heart transplantation: an open‐label study, Lancet Gastroenterol Hepatol, 4, 771, 10.1016/S2468-1253(19)30240-7 · doi:10.1016/s2468-1253(19)30240-7
- 2019, Fibrosing cholestatic hepatitis after kidney transplantation from HCV‐viremic donors to HCV‐negative recipients: a unique complication in the DAA era, Am J Transplant
- 2017, Favorable short‐term outcome of hepatitis C virus–positive liver graft with bridging fibrosis: a plea for very early viral eradication, Hepatology, 65, 2116, 10.1002/hep.28978 · doi:10.1002/hep.28978
- 2017, Transplanting HCV‐infected kidneys into uninfected recipients, N Engl J Med, 377, 1105
- 2017, Effect of hepatic impairment on the pharmacokinetics of grazoprevir, a hepatitis C virus protease inhibitor, Antimicrob Agents Chemother, 61
- 2018, The influence of immunosuppressants on direct‐acting antiviral therapy is dependent on the hepatitis C virus genotype, Transpl Infect Dis, 20
- 2017, Drug–drug interactions in hepatitis C virus treatment: do they really matter?, Clin Liver Dis (Hoboken), 10, 111, 10.1002/cld.668 · doi:10.1002/cld.668
- 2017, Decreased tacrolimus plasma concentrations during HCV therapy: a drug–drug interaction or is there an alternative explanation?, Int J Antimicrob Agents, 49, 379, 10.1016/j.ijantimicag.2016.12.004 · doi:10.1016/j.ijantimicag.2016.12.004
- 2016, Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct‐acting antivirals as treatment for hepatitis C infection, Ther Drug Monit, 38, 640, 10.1097/FTD.0000000000000315 · doi:10.1097/ftd.0000000000000315
- 2015, Drug interactions with direct‐acting antivirals for hepatitis C: implications for HIV and transplant patients, Ann Pharmacother, 49, 674, 10.1177/1060028015576180 · doi:10.1177/1060028015576180
- 2019, HCV NAT positive solid organ allografts transplanted into HCV negative recipients: a real‐world experience, Hepatology
- 2019, Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era, J Heart Lung Transplant, 38, 907, 10.1016/j.healun.2019.06.023 · doi:10.1016/j.healun.2019.06.023
- 2012, Early viral load and recipient interleukin‐28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation, Liver Transpl, 18, 671, 10.1002/lt.23402 · doi:10.1002/lt.23402
Cited by
Ryerson, A. B., Eheman, C. R., Altekruse, S. F., Ward, J. W., Jemal, A., Sherman, R. L., Henley, S. J., Holtzman, D., Lake, A., Noone, A., et al. (2016) · Cancer · doi:10.1002/cncr.29936 · Cited by 945
Global epidemiology of cirrhosis — aetiology, trends and predictions
Huang, D. Q., Terrault, N. A., Tacke, F., Gluud, L. L., Arrese, M., Bugianesi, E., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00759-2 · Cited by 839
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2575 · Cited by 688
Microfluidic Paper-Based Analytical Devices: From Design to Applications
Noviana, E., Ozer, T., Carrell, C. S., Link, J. S., McMahon, C., Jang, I., & Henry, C. S. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01335 · Cited by 631
Metadata
- Authors
- Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G.
- Venue
- Hepatology
- Published
- 2020-02
- Volume
- 71
- Issue
- 2
- Pages
- 686-721
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2992772421
- Cited by
- 955
- References
- 271
- FWCI
- 66.55
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- onlinelibrary.wiley.com/termsAndConditions#vor (vor, 9 d)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.